Stockreport

Savara (SVRA) Is Down 8.0% After FDA Grants Priority Review To MOLBREEVI - What's Changed [Yahoo! Finance]

Savara, Inc.  (SVRA) 
Last savara, inc. earnings: 3/12 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: savarapharma.com/investors/events-presentations
PDF alveolar proteinosis, granting Priority Review with a PDUFA action date of August 22, 2026. This filing adds to MOLBREEVI's existing Fast Track, Breakthrough Therapy, [Read more]